Key result
Familial combined hyperlipidemia is a clinically relevant polygenic disorder primarily affecting triglyceride metabolism that significantly increases cardiovascular risk and is closely associated with insulin resistance.
Why the study?
Although familial combined hyperlipidemia (FCHL) was first described as a multiple-type hyperlipidemia in pedigrees with premature myocardial infarction, what actually defines FCHL remains questioned.
Design
Review
Authors
Loading...
Encourages polygenic risk consideration in FCHL phenotyping; leaves open effects on targeted therapies.
This review reconceptualizes Familial Combined Hyperlipidemia as a polygenic rather than an autosomal dominant disorder, providing a new pathophysiological model for clinical guidance.
Brouwers et al. (2025) conducted a review in Familial Combined Hyperlipidemia (FCHL). Familial combined hyperlipidemia is a clinically relevant polygenic disorder primarily affecting triglyceride metabolism that significantly increases cardiovascular risk and is closely associated with insulin resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: